You are viewing the site in preview mode

Skip to main content

Advertisement

Table 8 Possible regimen changes in the ACCG scenario.

From: Cost-effectiveness analysis of guidelines for antihypertensive care in Finland

Initial drug 1st additional drug 2nd additional drug
thiazide diuretic ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) calcium channel blocker or beta blocker
thiazide diuretic beta blocker ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) or calcium channel blocker
calcium channel blocker (dihydropyridine derivatives) ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) thiazide diuretic or beta blocker
calcium channel blocker beta blocker ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) or thiazide diuretic
ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) thiazide diuretic calcium channel blocker or beta blocker
ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) calcium channel blocker thiazide diuretic or beta blocker
beta blocker thiazide diuretic ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) or calcium channel blocker
beta blocker calcium channel blocker ACE inhibitor (or angiotensin II subtype 1 receptor antagonist) or thiazide diuretic